Stock listing
NASDAQ:SLXN Silexion Therapeutics Corp Stock
Home listing (NASDAQ) of Silexion Therapeutics Corp
Follow Silexion Therapeutics Corp into a list and get an email when it puts out news.
Share price · NASDAQ:SLXN
$1.31 USD -0.13 (-9.0%)
Close on Nov 20, 2026
- Day range
- $1.28 – $1.40 USDNov 20, 2026
- Volume
- 15,877 sharesNov 20, 2026
- Market cap
- $790,001 USDAt the close on Nov 20, 2026 · price × 603,054 shares outstanding
- 52-week range
- $1.28 – $777.12 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $166,262 USDMedian day 2,030 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SLXN · Home | $1.31 USD | -0.13 (-9.0%) | 15,877 | $1.40 | $1.40 | $1.28 | $1.44 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLXN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.31 | -0.13 | -9.0% | $1.40 | $1.40 | $1.28 | 15,877 | |
| $1.44 | -0.21 | -12.7% | $1.61 | $1.65 | $1.44 | 23,740 | |
| $1.65 | -0.11 | -6.3% | $1.86 | $1.86 | $1.61 | 21,779 | |
| $1.76 | -0.22 | -11.1% | $1.98 | $1.98 | $1.74 | 23,219 | |
| $1.98 | -0.68 | -25.6% | $2.55 | $2.62 | $1.821 | 103,100 | |
| $2.66 | -0.57 | -17.6% | $3.105 | $3.24 | $2.64 | 70,700 | |
| $3.23 | +0.614 | +23.5% | $2.80 | $3.889 | $2.707 | 291,800 | |
| $2.616 | -0.36 | -12.1% | $2.928 | $2.928 | $2.568 | 26,567 | |
| $2.976 | -0.504 | -14.5% | $2.952 | $3.024 | $2.664 | 40,542 | |
| $3.48 | +0.024 | +0.7% | $3.648 | $3.648 | $3.456 | 335 | |
| $3.456 | -0.24 | -6.5% | $3.768 | $3.768 | $3.408 | 210 | |
| $3.696 | +0.024 | +0.7% | $3.672 | $3.792 | $3.624 | 222 | |
| $3.672 | +0.12 | +3.4% | $3.576 | $3.792 | $3.48 | 356 | |
| $3.552 | +0.072 | +2.1% | $3.624 | $3.696 | $3.48 | 544 | |
| $3.48 | +0.072 | +2.1% | $3.408 | $4.08 | $3.36 | 1,273 | |
| $3.408 | -0.264 | -7.2% | $3.792 | $4.20 | $3.408 | 1,037 | |
| $3.672 | -0.312 | -7.8% | $4.08 | $4.08 | $3.624 | 845 | |
| $3.984 | -0.216 | -5.1% | $4.296 | $4.296 | $3.84 | 1,693 | |
| $4.20 | -0.336 | -7.4% | $4.20 | $4.416 | $4.032 | 5,934 | |
| $4.536 | +0.576 | +14.5% | $4.056 | $4.68 | $3.864 | 4,882 | |
| $3.96 | 0.00 | 0.0% | $4.056 | $4.32 | $3.84 | 946 | |
| $3.96 | +0.264 | +7.1% | $4.104 | $4.104 | $3.84 | 498 | |
| $3.696 | +0.024 | +0.7% | $3.672 | $4.176 | $3.672 | 1,943 | |
| $3.672 | 0.00 | 0.0% | $3.936 | $4.392 | $3.408 | 8,891 | |
| $3.672 | -0.864 | -19.0% | $4.656 | $4.656 | $3.648 | 1,444 | |
| $4.536 | +0.432 | +10.5% | $4.104 | $4.68 | $4.032 | 4,912 | |
| $4.104 | -0.12 | -2.8% | $4.32 | $4.32 | $3.936 | 1,224 | |
| $4.224 | -0.048 | -1.1% | $4.512 | $4.656 | $3.912 | 3,625 | |
| $4.272 | -0.888 | -17.2% | $4.992 | $4.992 | $4.248 | 2,203 | |
| $5.16 | -0.48 | -8.5% | $5.52 | $5.568 | $4.992 | 1,426 | |
| $5.64 | -0.456 | -7.5% | $5.904 | $6.00 | $5.328 | 2,626 | |
| $6.096 | -0.216 | -3.4% | $5.928 | $6.192 | $5.904 | 1,867 | |
| $6.312 | -0.072 | -1.1% | $6.456 | $6.456 | $6.072 | 1,735 | |
| $6.384 | +0.144 | +2.3% | $6.264 | $6.48 | $6.168 | 2,142 | |
| $6.24 | -0.456 | -6.8% | $6.48 | $7.176 | $6.24 | 3,516 | |
| $6.696 | +0.048 | +0.7% | $6.192 | $7.008 | $5.904 | 5,736 | |
| $6.648 | -0.984 | -12.9% | $6.312 | $6.648 | $6.144 | 20,314 | |
| $7.632 | +1.68 | +28.2% | $7.656 | $9.60 | $7.152 | 445,432 | |
| $5.952 | -0.288 | -4.6% | $6.288 | $6.624 | $5.76 | 134,374 | |
| $6.24 | +0.072 | +1.2% | $5.76 | $6.48 | $5.664 | 2,030 | |
| $6.168 | -1.392 | -18.4% | $6.456 | $6.744 | $6.00 | 4,089 | |
| $7.56 | -1.848 | -19.6% | $8.136 | $9.168 | $7.20 | 14,500 | |
| $9.408 | -3.648 | -27.9% | $11.81 | $12.00 | $7.872 | 56,473 | |
| $13.06 | +2.592 | +24.8% | $10.08 | $15.12 | $9.96 | 34,944 | |
| $10.46 | +1.344 | +14.7% | $9.264 | $10.78 | $9.216 | 48,284 | |
| $9.12 | +0.96 | +11.8% | $8.784 | $9.36 | $8.352 | 14,787 | |
| $8.16 | 0.00 | 0.0% | $8.16 | $8.376 | $7.728 | 4,306 | |
| $8.16 | -1.08 | -11.7% | $8.04 | $8.52 | $7.776 | 64,181 | |
| $9.24 | +0.672 | +7.8% | $8.352 | $9.60 | $8.256 | 1,542 | |
| $8.568 | -1.584 | -15.6% | $8.64 | $9.312 | $8.136 | 4,476 | |
| $10.15 | +1.752 | +20.9% | $9.96 | $11.69 | $9.24 | 206,509 | |
| $8.40 | +0.12 | +1.4% | $8.28 | $8.544 | $8.04 | 116 | |
| $8.28 | -0.168 | -2.0% | $8.736 | $8.736 | $8.04 | 328 | |
| $8.448 | 0.00 | 0.0% | $8.928 | $9.12 | $8.448 | 352 | |
| $8.448 | +0.024 | +0.3% | $8.64 | $8.976 | $8.448 | 221 | |
| $8.424 | -0.456 | -5.1% | $9.12 | $9.36 | $8.40 | 318 | |
| $8.88 | 0.00 | 0.0% | $8.64 | $9.36 | $8.64 | 309 | |
| $8.88 | +0.168 | +1.9% | $8.856 | $9.024 | $8.64 | 268 | |
| $8.712 | +0.072 | +0.8% | $8.88 | $9.024 | $8.472 | 134 | |
| $8.64 | +0.12 | +1.4% | $8.40 | $9.12 | $8.40 | 497 | |
| $8.52 | -0.24 | -2.7% | $8.976 | $8.976 | $8.424 | 397 | |
| $8.76 | -0.072 | -0.8% | $8.64 | $8.928 | $8.544 | 339 | |
| $8.832 | -0.624 | -6.6% | $9.048 | $9.336 | $8.64 | 471 | |
| $9.456 | -0.12 | -1.3% | $9.336 | $9.744 | $9.048 | 394 | |
| $9.576 | -0.336 | -3.4% | $9.624 | $9.84 | $9.144 | 488 |
Splits
4 splits since 2024 · NASDAQ:SLXN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-24 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-9 | Consolidation |
- Ticker
- NASDAQ:SLXN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Aug 10, 2026
Investor Presentation (August 2026)
Investor deck · 27 slides
Latest news
Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 13, 2026
Closed $1.98 (-25.6%) on Nov 13, 2026
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
Nov 9, 2026
Closed $2.98 (-14.5%) on Nov 9, 2026
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Sep 30, 2026
Closed $6.65 (-12.9%) on Sep 30, 2026
Silexion Therapeutics Announces Exercise of Warrants
Sep 29, 2026
Closed $7.63 (+28.2%) on Sep 29, 2026
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
Sep 28, 2026
Closed $5.95 (-4.6%) on Sep 28, 2026
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
Sep 9, 2026
Closed $8.40 (+1.4%) on Sep 9, 2026
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 14, 2026
Closed $10.08 (-8.7%) on Aug 14, 2026
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Aug 11, 2026
Closed $10.90 (-56.1%) on Aug 12, 2026
Silexion Therapeutics Corp on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 59 in all · newest Nov 13, 2026 · oldest 2024
- Decks
- 9 decks · latest Aug 10, 2026
Where Silexion Therapeutics Corp is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SLXN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SLXN | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 0.3×: 5th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.60M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 2.77
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Silexion Therapeutics Corp · NASDAQ:SLXN | US$790,001 | −US$3.60M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 2.77 |
| SureNano Science Ltd · CSE:SURE | US$1.17M | US$672,321 | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.25 |
| Valion Bio, Inc. · NASDAQ:VBIO | US$1.04M | US$16.34M | n/a | 42.8× | n/a | 0.2× | n/a | 4.1× | 1.11 |
| GeoVax Labs, Inc. · NASDAQ:GOVX | US$985,460 | −US$915,033 | n/a | n/a | n/a | 0.9× | n/a | 0.2× | 1.47 |
| Biodexa Pharmaceuticals plc · NASDAQ:BDRX | US$982,950 | −US$3.22M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.01 |
| Gabather AB · OMXSTO:GABA | US$920,657 | US$559,800 | n/a | n/a | n/a | 6.4× | n/a | 0.0× | n/a |
| ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2 | US$793,620 | −US$2.43M | n/a | −6.5× | n/a | 0.2× | −935.9% | 0.0× | n/a |
| Oragenics Inc. · AMEX:OGEN | US$708,377 | −US$1.12M | n/a | n/a | n/a | 0.7× | n/a | 0.4× | 1.47 |
| Protagenic Therapeutics, Inc. · OTC:PTIX | US$687,879 | US$610,970 | 0.1× | n/a | n/a | 0.6× | n/a | 0.0× | 1.21 |
| Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABT | US$580,337 | −US$2.74M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.46 |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Median of the others | US$857,139 | −US$177,617 | 0.1× | 18.1× | 0.3× | −935.9% | 0.0× | 1.16 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 120.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -112.80 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Mirit Horenshtein Hadar | Chief Financial Officer |
| Michal Yaron | VP RA |
| Orit Pollack Shragai | VP Clinical Operations |
| Racheli Gabai-Malka | VP Pharmaceutical Development |
| Mitchell Shirvan | Chief Scientific and Development Officer |
Board
| Director | Role |
|---|---|
| Ilan Hadar | Chairman |
| Avner Lushi | Director |
| Dror Abramov | Director |
| Ruth Alon | Director |
| Shlomo Noy | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | −38.7% |
| Q2 2026 | Aug 14, 2026 · Before open | −8.7% |
| Q1 2026 | May 15, 2026 · After close | −5.2% |
| Q4 2025 | Mar 18, 2026 | −7.8% |
| Q3 2025 | Nov 12, 2025 · Before open | +3.6% |
| Q2 2025 | Aug 7, 2025 · After close | −4.1% |
| Q1 2025 | May 13, 2025 · After close | −0.9% |
| Q4 2024 | Mar 18, 2025 · After close | −11.2% |
| Q3 2024 | Nov 14, 2024 · Before open | −8.6% |
| Q2 2024 | Aug 13, 2024 · Before open | −12.1% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | 0.0% |
| Q4 2022 | Mar 31, 2023 | +0.2% |
| Q3 2022 | Nov 14, 2022 | +0.1% |
| Q2 2022 | Aug 15, 2022 | 0.0% |
| Q1 2022 | May 23, 2022 | 0.0% |
| Q4 2021 | Mar 31, 2022 | +0.4% |
| Quarter to Sep 30, 2021 | Nov 9, 2021 | +0.2% |
| Quarter to Jun 30, 2021 | Aug 16, 2021 | −0.6% |
| Quarter to Mar 31, 2021 | May 25, 2021 | −0.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 27 slides | Aug 10, 2026 |
| Investor Presentation (February 2026) | Investor deck | 34 slides | Feb 3, 2026 |
| Investor Presentation (February 2026) | Investor deck | 32 slides | February 2026 |
| Investor Presentation (August 2025) | Investor deck | 32 slides | August 2025 |
| Investor Presentation (March 2025) | Investor deck | 32 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 31 slides | Jan 15, 2025 |
| Investor Presentation (December 2024) | Investor deck | 33 slides | December 2024 |
| Investor Presentation (September 2024) | Investor deck | 30 slides | Sep 9, 2024 |
| SPAC Merger (July 2024) | SPAC merger | 24 slides | Jul 25, 2024 |
Financings
| Raise | Date |
|---|---|
| Ordinary shares on exercise of series E warrants Announced: US$837,366 · US$0.2603 a share · Warrants at US$0.2603 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Sep 29, 2026 |
| Public offering of ordinary shares Closed: US$2.5M raised · US$0.65 a share · Warrants at US$0.65 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Strengthen the balance sheet, support the Phase 2/3 trial of SIL204 and support Nasdaq continued listing compliance | Aug 14, 2026 |
| Public offering of ordinary shares (or ordinary share equivalents) with series A and series B warrants Announced: US$6M · US$4 a share · Warrants at US$4 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Advance pre-clinical studies and general corporate purposes | Sep 11, 2025 |
| Warrant exercise of ordinary shares on exercise of warrants Announced: about US$1.8M · US$11.57 a share · Warrants at US$11.32 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Aug 1, 2025 |
| Warrant exercise of ordinary shares on exercise of outstanding warrants Announced: about US$3.3M · US$1.35 a share · Warrants at US$1.5 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital for general corporate purposes | Jan 29, 2025 |
| Public offering of ordinary shares (or ordinary share equivalents) and warrants Announced: about US$5M · US$1.35 a share · Warrants at US$1.35 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Advance pre-clinical studies and general corporate purposes | Jan 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2012 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 14.0K | 25.0K | |||||
| Gross profit | -14.0K | -25.0K | |||||
| Research and development | 7.14M | 5.82M | 3.71M | 3.23M | |||
| Selling, general and administrative | 4.48M | 6.73M | 928.0K | 577.0K | |||
| Operating income | -11.6M | -12.6M | -4.68M | -3.86M | -943.9K | -195.9K | |
| Depreciation and amortization | 14.0K | 25.0K | 45.0K | 57.0K | 2.00K | ||
| EBITDA | -11.6M | -12.5M | -4.64M | -3.80M | |||
| Interest expense | 13.0K | 52.0K | 9.00K | 85.0K | |||
| Income before tax | -11.9M | -16.5M | -5.08M | -3.46M | -755.2K | -195.9K | |
| Income tax | 3.00K | 10.0K | 32.0K | 24.0K | |||
| Net income | -11.9M | -16.5M | -5.11M | -3.21M | -755.2K | -195.9K | |
| Earnings per share, basic | 8.96 | 394.94 | 44.23 | -68.64 | -17.80 | ||
| Earnings per share, diluted | 8.96 | 394.94 | 44.23 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.99M | 1.19M | 4.59M | 8.26M | 38.9K | 51.7K | ||
| Short-term investments | 35.0K | |||||||
| Receivables | 89.0K | 161.0K | ||||||
| Current assets | 6.64M | 2.25M | 4.98M | 8.84M | 407.8K | 51.7K | 928.0K | 1.79M |
| Property, plant and equipment | 25.0K | 30.0K | 49.0K | 9.00K | 7.00K | |||
| Total assets | 7.21M | 2.86M | 5.26M | 9.33M | 115.4M | 129.4K | ||
| Accounts payable | 787.0K | 929.0K | 319.0K | 240.0K | 102.0K | 81.0K | ||
| Current liabilities | 2.76M | 3.52M | 2.20M | 1.61M | 348.6K | 29.4K | 241.0K | 168.0K |
| Long-term debt | 1.57M | 2.96M | ||||||
| Total debt | 468.0K | 4.49M | 171.0K | 271.0K | ||||
| Total liabilities | 4.61M | 6.85M | 2.25M | 16.4M | 508.9K | 299.4K | ||
| Shareholders' equity | 2.60M | -3.99M | -15.5M | -10.7M | 114.9M | -170.0K | ||
| Shares outstanding | 13.0K | 123.3M | 97.1M | 465 | 11.0K | 11.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2012 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -10.8M | -8.40M | -4.53M | -3.33M | -1.41M | -75.0K | -911.0K |
| Capital spending | -9.00K | -22.0K | -12.0K | -40.0K | -4 | 0 | -3.00K |
| Free cash flow | -10.8M | -8.42M | -4.54M | -3.38M | -1.41M | -75.0K | -914.0K |
| Cash from investing | -14.0K | -22.0K | 573.0K | -524.0K | -28.0K | ||
| Cash from financing | 15.6M | 5.10M | 522.0K | 2.75M | 116.4M | 126.7K | 1.72M |
| Change in cash | 4.81M | -3.31M | -3.43M | -1.77M | -12.8K | 51.7K | 782.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 10, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| S-3 · Registration statement | Oct 28, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 26, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Oct 19, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 5, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 424B3 · Prospectus | Sep 29, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 29, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 8-K · Current report | Sep 25, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Sep 25, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 25, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 16, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Sep 9, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 25, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 19, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 14, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 8-K · Current report | Aug 13, 2026 | Current report | SEC |
| 8-K · Current report | Aug 13, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Aug 13, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 12, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 10, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| S-1 · Registration statement | Aug 7, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 4, 2026 | Current report | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 8-K · Current report | Jul 31, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 29, 2026 | Current report | SEC |
| 8-K · Current report | Jul 21, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 13, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 23, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 22, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jun 18, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Jun 16, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Jun 16, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 15, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 12, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Jun 3, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 29, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 28, 2026 | Offer document | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 10-K/A · Annual report, amended | May 19, 2026 | Annual report | SEC |
| 8-K · Current report | May 18, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | May 7, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | May 7, 2026 | Offer document | SEC |
| 8-K · Current report | May 5, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 9, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 31, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 25, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 24, 2026 | Current report | SEC |
| 8-K · Current report | Mar 23, 2026 | Meeting outcome | SEC |
| DRS · Draft registration statement | Mar 17, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 16, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Feb 23, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Feb 19, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 16, 2025 | Current report | SEC |
| 8-K · Current report | Dec 2, 2025 | Current report | SEC |
| 8-K · Current report | Nov 25, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| S-3 · Registration statement | Oct 31, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 30, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 29, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 26, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 26, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 25, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 23, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 15, 2025 | Financing | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 12, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Sep 12, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 12, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 5, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 5, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 424B3 · Prospectus | Sep 4, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 28, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 26, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 20, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| 8-K · Current report | Aug 19, 2025 | Meeting outcome | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 12, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| D | Aug 11, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 1, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 31, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Jul 31, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 29, 2025 | Current report | SEC |
| 8-K · Current report | Jul 21, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jul 21, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 16, 2025 | Current report | SEC |
| 8-K · Current report | Jul 14, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Jul 8, 2025 | Current report | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jul 7, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 26, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jun 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 16, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 30, 2025 | Other filings | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| 424B3 · Prospectus | May 13, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 13, 2025 | Offer document | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 6, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 2, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 29, 2025 | Offer document | SEC |
| AW | Apr 29, 2025 | Other filings | SEC |
| AW | Apr 29, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 29, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 28, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 28, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 23, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| DRS · Draft registration statement | Apr 23, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 10, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 1, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 28, 2025 | Current report | SEC |
| S-1/A · Registration statement, amended | Mar 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Mar 14, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 14, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Feb 19, 2025 | Other filings | SEC |
| S-1 · Registration statement | Feb 12, 2025 | Offer document | SEC |
This page holds 200 of 285 filings. Open Filings
Cap table
Built by 6ix from Silexion Therapeutics Corp’s releases · as of Nov 11, 2026
- Common shares
- 603,054
- Fully diluted
- 603,054
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 603,054 | Nov 11, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.65 · expire about Aug 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 603,054 |
| Nov 11, 2026 | |
| Nov 9, 2026 | |
| Sep 30, 2026 | 603,055 |
| May 26, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ruth Alon Other companies: Alpha Tau Medical Ltd (Director · Since at least Mar 18, 2026); Vascular Biogenics Ltd (Director · Jan 1, 2023 – Jan 1, 2023 · Past); Moringa Acquisition Corp (Director · Feb 16, 2021 – Feb 16, 2021 · Past); Chemomab Therapeutics Ltd. (Director · Jan 1, 2020 – Jan 1, 2020 · Past) | Director · Since at least Aug 15, 2024 |
| Avner Lushi Other companies: BrainsWay Ltd (Director · Since at least Mar 18, 2026) | Director · Since at least Aug 15, 2024 |
| Ilan Levin Other companies: Moringa Acquisition Corp (Chairman and CEO, Director · Feb 16, 2021 – Feb 16, 2021 · Past) | Director · Since at least Aug 15, 2024 |
| Amnon Peled | Director · Since at least Dec 10, 2024 |
| Dror Abramov | Director · Since at least Aug 15, 2024 |
| Hadar Mirit Horenshtein | CFO and Secretary · Since at least Aug 15, 2024 |
| Ilan Hadar | Chairman · Since at least Aug 15, 2024 |
| Ilan Shiloah | Director · Aug 15, 2024 – Aug 15, 2024 · Past |
| Michal Yaron | VP RA · Since at least Nov 4, 2026 |
| Mirit Horenshtein Hadar | Chief Financial Officer · Since at least Sep 9, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Mitchell Shirvan | Chief Scientific and Development Officer · Since at least Aug 15, 2024 |
| Orit Pollack Shragai | VP Clinical Operations · Since at least Nov 4, 2026 |
| Racheli Gabai-Malka | VP Pharmaceutical Development · Since at least Nov 4, 2026 |
| Shlomo Noy | Director · Since at least Aug 15, 2024 |
| Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar | Capital Markets Advisors for Silexion · Jan 15, 2025 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Silexion Therapeutics Corp.